MedTrace Logo

Comparative Effectiveness and Safety Between Warfarin and Dabigatran

NCT03254134 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22490

Last updated 2019-07-09

Study results available
· View outcomes & findings →

Summary

This is a comparative effectiveness and safety study of clinical events among patients taking either dabigatran or warfarin. There is no formal hypothesis to be tested, but rather to provide the estimates on the incidence of stroke and systemic embolism (effectiveness) and bleeding events (safety) using 95% confidence interval for comparison between those non0-valvular atrial fibrillation patients taking dabigatran vs. warfarin using a large, nation-wide claims data in Japan.

Conditions

Interventions

DRUG

Warfarin

patients treated with warfarin

DRUG

Dabigatran

patients treated with Dabigatran

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-20
Primary Completion
2017-10-30
Completion
2017-11-03
FDA Drug
Yes

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03254134 on ClinicalTrials.gov